ATEA PHARMACEUTICALS, INC. — Earnings
Most recent reported period: FY2021 (Q4) (filed for period ending 2021-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Fri, April 1, 2022 — 1491 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | — | — | — |
| 2025-09-30 | — | — | $-42M | ↓-35.0% | — |
| 2025-06-30 | — | — | $-37M | ↑+8.3% | — |
| 2025-03-31 | — | — | $-34M | ↑+45.7% | — |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | — | — | $-31M | ↑+6.0% | — |
| 2024-06-30 | — | — | $-41M | ↓-43.8% | — |
| 2024-03-31 | — | — | $-63M | ↓-78.1% | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2021 (Q4)
Revenue
$192M
Net Income
$117M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
AVIR Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyAVIR Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics